Zobrazeno 1 - 10
of 45
pro vyhledávání: '"Andrew T Miller"'
Autor:
Andrew T Miller, Carol Dahlberg, Mark L Sandberg, Ben G Wen, Daniel R Beisner, John A H Hoerter, Albert Parker, Christian Schmedt, Monique Stinson, Jacqueline Avis, Cynthia Cienfuegos, Mark McPate, Pamela Tranter, Martin Gosling, Paul J Groot-Kormelink, Janet Dawson, Shifeng Pan, Shin-Shay Tian, H Martin Seidel, Michael P Cooke
Publikováno v:
PLoS ONE, Vol 10, Iss 6, p e0131071 (2015)
Emerging approaches to treat immune disorders target positive regulatory kinases downstream of antigen receptors with small molecule inhibitors. Here we provide evidence for an alternative approach in which inhibition of the negative regulatory inosi
Externí odkaz:
https://doaj.org/article/60911ac9821349a2a5779985bf95458d
Autor:
Chih-Yuan Chiang, Douglas J. Lane, Yefen Zou, Tim Hoffman, Jianfeng Pan, Janice Hampton, Jillian Maginnis, Bishnu P. Nayak, Ugo D’Oro, Nicholas Valiante, Andrew T. Miller, Michael Cooke, Tom Wu, Sina Bavari, Rekha G. Panchal
Publikováno v:
Frontiers in Microbiology, Vol 13 (2022)
Current therapies for anthrax include the use of antibiotics (i.e., doxycycline, and ciprofloxacin), an anthrax vaccine (BioThrax) and Bacillus anthracis-specific, monoclonal antibody (mAb) (i.e., Raxibacumab and obiltoxaximab). In this study, we inv
Externí odkaz:
https://doaj.org/article/3ab3d25f2f914680b584dec5a98275c9
Autor:
Chih-Yuan, Chiang, Douglas J, Lane, Yefen, Zou, Tim, Hoffman, Jianfeng, Pan, Janice, Hampton, Jillian, Maginnis, Bishnu P, Nayak, Ugo, D'Oro, Nicholas, Valiante, Andrew T, Miller, Michael, Cooke, Tom, Wu, Sina, Bavari, Rekha G, Panchal
Publikováno v:
Frontiers in microbiology. 13
Current therapies for anthrax include the use of antibiotics (i.e., doxycycline, and ciprofloxacin), an anthrax vaccine (BioThrax) and
Autor:
Changsuek Yon, Xu Huang, Tom Y.-H. Wu, Bin Li, Manny Corpuz, David M. Plouffe, Kyle E. Korolowizc, Evelyn Rodrigo, Manasa Suresh, Bhaskar Kallakury, Stephan Menne, Andrew T. Miller
Publikováno v:
Hepatology Communications
Hepatology Communications, Vol 3, Iss 10, Pp 1296-1310 (2019)
Hepatology Communications, Vol 3, Iss 10, Pp 1296-1310 (2019)
Current therapeutics for chronic infection with hepatitis B virus (HBV) rarely induce functional cure due to the immunotolerant status of patients. Small molecule agonists targeting toll‐like receptor 7 (TLR7) have been shown to elicit a functional
Autor:
Andrew Kemal Kirchmeier, Corey Cutler, Jerome Ritz, Ryan Flynn, Andrew T. Miller, Jonathan S. Serody, Ivan Maillard, John Koreth, Carol Dahlberg, Michael Loschi, Bruce R. Blazar, David B. Miklos, Angela Panoskaltsis-Mortari, Leo Luznik, Patricia A. Taylor, Kelli P. A. MacDonald, Robert J. Soiffer, Michael Zaiken, Govindarajan Thangavelu, William J. Murphy, David H. Munn, Joseph H. Antin, Jing Du, Geoffrey R. Hill, Katelyn Paz
Publikováno v:
Blood
T-cell activation releases inositol 1,4,5-trisphosphate (IP(3)), inducing cytoplasmic calcium (Ca(2+)) influx. In turn, inositol 1,4,5-trisphosphate 3-kinase B (Itpkb) phosphorylates IP(3) to negatively regulate and thereby tightly control Ca(2+) flu
Autor:
Ugo D'Oro, Chun Li, Kathy Yue, Michael P. Cooke, Janice Hampton, Andrew T. Miller, M. Lamine Mbow, Nicholas Valiante, David A. G. Skibinski, Xiaoyue Zhang, De Shon Hall, Michael Shapiro, Derek T. O'Hagan, Manmohan Singh, Tom Y.-H. Wu, Bishnu P. Nayak, Jillian Maginnis, Yongkai Li, Alex Cortez
Publikováno v:
Journal of Medicinal Chemistry. 59:5868-5878
Small molecule Toll-like receptor 7 (TLR7) agonists have been used as vaccine adjuvants by enhancing innate immune activation to afford better adaptive response. Localized TLR7 agonists without systemic exposure can afford good adjuvanticity, suggest
Autor:
Abdallah G. Kfoury, Bruce B. Reid, K. Afshar, Sean P. McCandless, B.Y. Rasmusson, Rami Alharethi, H.K. Smith, G. Andrew Wright, Alexis K. Johnson, William T. Caine, Deborah Budge, Andrew T. Miller, S. Stoker, A. Rauf
Publikováno v:
Clinical Transplantation. 30:195-201
BACKGROUND Ventricular assist devices (VADs) have a proven survival benefit in select patients with advanced heart failure, yet many patients considered for implantation are declined for various reasons. The outcome of these patients is obscure owing
Publikováno v:
Cancer Research. 80:684-684
Anti-PD1/L1 has become the backbone of immune therapy for many cancer types. However, the majority of patients do not respond due to a myriad of mechanisms affecting the tumor microenvironment, including low tumor mutational burden and low immune cel
Autor:
Andrew T. Miller, Tom Y.-H. Wu, Luis Brito, Manmohan Singh, Derek T. O'Hagan, Rushit N. Lodaya, Gillis R. Otten
Publikováno v:
Journal of pharmaceutical sciences. 107(9)
Adjuvants are required to enhance immune responses to typically poorly immunogenic recombinant antigens. Toll-like receptor agonists (TLRa) have been widely evaluated as adjuvants because they activate the innate immune system. Currently, licensed va
Autor:
David Raubenheimer, Scott Joseph Mcgrane, Andrew T. Miller, Richard F. Butterwick, Alison Colyer, Simon Reginald Hall, Stephen J. Simpson, Victoria L. Hewson-Hughes, Adrian K. Hewson-Hughes
Publikováno v:
Behavioral Ecology
Although many herbivores and omnivores have been shown to balance their intake of macronutrients when faced with nutritionally variable foods, study of this ability has been relatively neglected in carnivores, largely on the assumption that prey are